vTv Ther­a­peu­tics re­ports ad­di­tion­al pos­i­tive PhII da­ta; Shang­hai Hen­lius prices $410 mil­lion IPO at bot­tom of range

→ vTv Ther­a­peu­tics — fo­cused on the de­vel­op­ment of oral small mol­e­cule drug can­di­dates — has un­veiled ad­di­tion­al pos­i­tive da­ta from its Phase II Sim­pli­ci-T1 study in pa­tients with type 1 di­a­betes (T1D). CSO Car­men Val­carce pre­sent­ed new con­tin­u­ous glu­cose mon­i­tor (CGM) and in­sulin dose da­ta from pa­tients with com­plete CGM pro­files in the com­plet­ed Phase II – Part 1 of the study, which in­cludes:

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER